All In Biotech

Free tool

FAERS Monitor: Tobradex St

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 050818 or its brand name (Tobradex St, Dexamethasone, Tobramycin). Reports on generic versions are filed under their own applications.

Reports

130

Serious

46

35% of reports

Hospitalization

23

Death reported

4

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • eye pain17
  • ocular hyperaemia10
  • vision blurred10
  • product dose omission issue9
  • condition aggravated7
  • headache7
  • drug ineffective6
  • eye irritation6
  • eyelid pain5
  • off label use5
  • photophobia5
  • anxiety4
  • eye swelling4
  • fall4
  • infection4

Reports by year received

View as table
YearReports
20062
20101
20112
20124
20131
20141
20151
20163
20175
20187
201919
202016
202114
20221
202312
202414
202523
20264

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,029 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
eyelid painSignal5399.1168.81,604
eye painSignal1748.831.3750
photophobiaSignal543.018.2165
ocular hyperaemiaSignal1034.118.8290
eye swellingSignal417.46.647
eye irritationSignal616.97.775
vision blurredSignal1011.86.589
product dose omission issueSignal95.02.625
infectionSignal44.51.78
condition aggravatedSignal73.71.812
anxiety42.30.92
fall41.90.71
headache71.80.92
off label use50.90.40
drug ineffective60.70.30

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.